WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

https://hk.investing.com/news/stock-market-news/article-226181

WuXi Biologics (02269) Subsidiary Granted 53,067,270 Share Options https://m.jrj.com.cn/madapter/hk/2022/04/03180836251930.shtml

BlackRock reduzierte seine Bestände von etwa 979.200 Aktien von WuXi Biologics (02269 HK) zu etwa 55,14 HK$ pro Aktie -> 22.03. https://m.sohu.com/a/533365103_121319643/?pvid=000115_3w_a Morgan Stanley: Raised the target price of WuXi Biologics (2269 HK) to HK$86 with an overweight rating https://m.jrj.com.cn/madapter/hk/2022/03/28131235846160.shtml

WuXi Bio grabs larger piece of the bio CDMO pie https://bioprocessintl.com/bioprocess-insider/global-markets/wuxi-bio-grabs-larger-piece-of-the-bio-cdmo-pie/ Credit Suisse: Maintain "Outperform" rating on WuXi Biologics (02269), target price down to HK$110 https://m.jrj.com.cn/madapter/hk/2022/03/25121135078884.shtml

https://wap.eastmoney.com/a/202203232320263176.html

https://hk.investing.com/news/stock-market-news/article-222049

WuXi Biologics Achieved Record Growth and Profitability in 2021 https://www.prnewswire.com/news-releases/wuxi-biologics-achieved-record-growth-and-profitability-in-2021-301508083.html Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to US$13,597 Million ....

https://m.jrj.com.cn/madapter/hk/2022/03/22201234862242.shtml

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021 https://doc.irasia.com/listco/hk/wuxibiologics/annual/2021/res.pdf

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1169873/1

Yamato: Upgrading WuXi Biologics (02269) to “Buy” and lowering the target price to HK$72 https://finance.sina.cn/hkstock/ggpj/2022-03-18/detail-imcwipih9178908.d.html?from=wap

https://finance.sina.cn/hkstock/ggpj/2022-03-17/detail-imcwipih9058299.d.html?from=wap ... Considering that CXO companies are not affected by the temporary slowdown in medical terminal demand, and WuXi PharmaTech (2359 HK), Tigermed (3347 HK), and Asymchem (6821 HK) have recently announced that they will be in January-February 2022 New orders increased significantly year-on-year, indicating that the industry's prosperity is still high. We still recommend WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK).  ... The share price of WuXi Biologics (2269 HK) has already reflected the impact of two of its subsidiaries being included in the "unverified list" by the United States earlier. ... Therefore, the actual impact of the US policy on the company's operation is controllable at present. We maintain a "buy" rating and a target price of HK$114.66. 

10 Yuan wäre natürlich bitter. Ich hoffe, dass bald wieder Vernunft in die Märkte einkehrt.

Der Aktienkurs von WuXi Biologics ist um 70 % gefallen, PEG sucht nach einem angemessenen Preis https://hk.investing.com/news/stock-market-news/article-220379

HSI Once Deepens Slide to over 500 pts; HKEX, ANTA, LI NING, WUXI BIO Down 5-10% http://www.aastocks.com/en/stocks/news/aafn-con/rum.220309_112437/latest-news Changes in Hong Kong Stocks | CXO stocks fell collectively, WuXi Biologics (02269) fell more than 8% 1Q22 industry chain prosperity may be flat, institutions suggest to wait and see the sector cautiously https://m.jrj.com.cn/madapter/finance/2022/03/09120134544071.shtml